Definium Therapeutics, Inc.
DFTX
Rang in Aktien
#3499
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aktienkurs
$35.95
Marktkapitalisierung
$4.83B
Veränderung (1 Tag)
1.31%
Veränderung (1 Jahr)
239.21%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Kategorie
Healthcare
Kursverlauf für Definium Therapeutics, Inc. (DFTX)
Höchster Schlusskurs: $10.57 am 2024-04-01
Niedrigster Schlusskurs: $4.87 am 2020-03-01
Niedrigster Schlusskurs: $4.87 am 2020-03-01
Kursverlauf der Aktie von Definium Therapeutics, Inc. von 2020 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $535.96 | 25.68% |
US
|
|
| $186.23 | 593.59% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $892.29 | 9.59% |
NL
|
